Release date: 2024-07-09 17:05:57 Article From: Lucius Laos Recommended: 166
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an inactive GDP-bound state, it inhibits signal transduction, thereby impeding the driving force behind cell growth.
Sotorasib is primarily used to treat adult patients with locally advanced or NSCLC carrying the FDA-approved KRAS G12C mutation. These patients have typically undergone at least one systemic therapy with inadequate disease control. The emergence of Sotorasib offers new therapeutic options for these patients.
Sotorasib is a prescription drug, and patients should strictly adhere to medical advice, taking the medication as prescribed and avoiding unauthorized alterations to the dosage. Prior to use, patients should carefully review the drug information leaflet to understand precautions, dosages, and potential drug interactions, mitigating any risk of indiscriminate usage.
Patients using Sotorasib should heed their physicians' recommendations and consider the following points. Any discomfort or uncertainties encountered during medication should prompt immediate medical consultation.
Regular liver function tests are advised during Sotorasib administration to monitor changes in liver enzymes and function indicators. Prompt medical attention is necessary in cases of abnormal liver function.
Some patients may experience diarrhea post-Sotorasib use. Healthcare professionals may prescribe medications based on individual patient circumstances to manage this symptom.
Lung function monitoring is particularly crucial for NSCLC patients. Patients should monitor changes in respiratory symptoms, such as new or worsening dyspnea, and promptly report to their healthcare provider.
[Warm tips] Patients using Sotorasib should strictly adhere to prescribed treatment regimens and avoid adjusting dosages or discontinuing medication without medical advice. Any discomfort or unusual symptoms during use should be promptly reported to a doctor for assistance.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: